Clinical trial results:
A multi-centre, randomised, double-blind, placebo-controlled, dose ranging study to evaluate the safety and efficacy of GSK2586184 in patients with chronic plaque psoriasis

Summary

EudraCT number	2012-002917-20
Trial protocol	GB DE
Global end of trial date	24 March 2014

Results information

Result version number	v1 (current)
This version publication date	15 March 2016
First version publication date	27 May 2015

Trial information

Trial identification

Sponsor protocol code	JAK116679

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01782664
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	GlaxoSmithKline
Sponsor organisation address	980 Great West Road, Brentford, Middlesex, United Kingdom,
Public contact	GSK Response Center, GlaxoSmithKline, +1 8664357343,
Scientific contact	GSK Response Center, GlaxoSmithKline, +1 8664357343,

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	02 May 2014
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	24 March 2014
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To estimate the relationship between dose of GSK2586184 and clinical response as assessed by PASI score after 12 weeks of
treatment in patients with moderate to severe plaque-type psoriasis.

Protection of trial subjects:

Measures to protect trial subjects:
- Routine safety monitoring (safety laboratory tests, physical examinations, vital signs and ECGs) to detect any adverse reactions, and in particular, regular AE checks and temperature monitoring to detect any signs of infection.
- Study specific withdrawal criteria for changes in haematological parameters, renal function, liver chemistry, QTc, infection, adverse events and worsening of psoriasis symptoms.
- Ongoing review of blinded safety data by the sponsor safety review team.
- Protocol-specified contraception requirements to prevent subject pregnancy.
- Measures to reduce sun exposure during the treatment phase.
- Prohibited medications to reduce the risk of drug interactions.
- All study procedures were non-invasive, except for blood sampling and the skin biopsies taken from subjects enrolled in Cohort B. A local anaesthetic was administered before each skin biopsy. All biopsies were conducted by experienced personnel to reduce the risk of bleeding, scarring and infection.

Background therapy: -
Evidence for comparator: -

Actual start date of recruitment	12 March 2013
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Germany: 56
Country: Number of subjects enrolled	United Kingdom: 12
Worldwide total number of subjects	68
EEA total number of subjects	68

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0

Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	60
From 65 to 84 years	8
85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

Participants with a diagnosis of moderate to severe plaque type psoriasis for at least 12 months before the first dose of study medication, who were otherwise healthy, were included in the study.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Data analyst, Assessor

Arms

Are arms mutually exclusive?	Yes
Arm title	Placebo

Arm description:

Participants received blinded matching placebo orally as tablets, with food, twice daily (BID), for up to 12 weeks.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Placebo tablets taken twice daily with food for up to 84 days.

Arm title	GSK2586184 100 mg

Arm description:

Participants received blinded 100 milligrams (mg) GSK2586184 orally as tablets, with food, BID, for up to 12 weeks.

Arm type	Experimental
Investigational medicinal product name	GSK2586184
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

100 mg GSK2586184 taken twice daily with food (as tablets) for up to 84 days

Arm title	GSK2586184 200 mg

Arm description:

Participants received blinded 200 mg GSK2586184 orally as tablets, with food, BID, for up to 12 weeks.

Arm type	Experimental
Investigational medicinal product name	GSK2586184
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

200 mg GSK2586184 taken twice daily with food (as tablets) for up to 84 days

Arm title	GSK2586184 400 mg

Arm description:

Participants received blinded 400 mg GSK2586184 orally as tablets, with food, BID, for up to 12 weeks.

Arm type	Experimental
Investigational medicinal product name	GSK2586184
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

400 mg GSK2586184 taken twice daily with food (as tablets) for up to 84 days

Arm title	GSK2586184 400 mg OL

Arm description:

Participants received Open-Label 400 mg GSK2586184 orally as tablets, with food, BID, for up to 12 weeks.

Arm type	Experimental
Investigational medicinal product name	GSK2586184
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

400 mg GSK2586184 taken twice daily with food (as tablets) for up to 84 days

Arm title	GSK2586184 200 mg OL

Arm description:

Participants incorrectly received Open-Label 200 mg (rather than 400 mg) GSK2586184 orally as tablets, with food, BID, for up to 12 weeks.

Arm type	Experimental
Investigational medicinal product name	GSK2586184
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

200 mg GSK2586184 taken twice daily with food (as tablets) for up to 84 days

Number of subjects in period 1[1]	Placebo	GSK2586184 100 mg	GSK2586184 200 mg
Started	14	15	16
Completed	8	10	12
Not completed	6	5	4
Consent withdrawn by subject	2	2	-

Adverse event, non-fatal	2	2	2
Lack of efficacy	2	-	2
Protocol deviation	-	1	-

Number of subjects in period 1[1]	GSK2586184 400 mg	GSK2586184 400 mg OL	GSK2586184 200 mg OL
Started	14	6	2
Completed	9	6	2
Not completed	5	0	0
Consent withdrawn by subject	-	-	-
Adverse event, non-fatal	2	-	-
Lack of efficacy	2	-	-
Protocol deviation	1	-	-

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.
Justification: Of the 68 subjects randomised, 1 subject did not receive any medication and therefore is not included in the baseline characteristic data.

Baseline characteristics

Reporting groups	
Reporting group title	Placebo
Reporting group description:	
Participants received blinded matching placebo orally as tablets, with food, twice daily (BID), for up to 12 weeks.	
Reporting group title	GSK2586184 100 mg
Reporting group description:	
Participants received blinded 100 milligrams (mg) GSK2586184 orally as tablets, with food, BID, for up to 12 weeks.	
Reporting group title	GSK2586184 200 mg
Reporting group description:	
Participants received blinded 200 mg GSK2586184 orally as tablets, with food, BID, for up to 12 weeks.	
Reporting group title	GSK2586184 400 mg
Reporting group description:	
Participants received blinded 400 mg GSK2586184 orally as tablets, with food, BID, for up to 12 weeks.	
Reporting group title	GSK2586184 400 mg OL
Reporting group description:	
Participants received Open-Label 400 mg GSK2586184 orally as tablets, with food, BID, for up to 12 weeks.	
Reporting group title	GSK2586184 200 mg OL
Reporting group description:	
Participants incorrectly received Open-Label 200 mg (rather than 400 mg) GSK2586184 orally as tablets, with food, BID, for up to 12 weeks.	

Reporting group values	Placebo	GSK2586184 100 mg	GSK2586184 200 mg
Number of subjects	14	15	16
Age categorical Units: Subjects			
Age continuous Units: years			
arithmetic mean	49	43.9	49
standard deviation	± 13.79	± 14.1	± 13.24
Gender categorical Units: Subjects			
Female	5	6	6
Male	9	9	10
Race, Customized Units: Subjects			
African American/African Heritage	0	0	2
Asian - South East Asian Heritage	0	1	0
White - White/Caucasian/European Heritage	14	14	14

Reporting group values	GSK2586184 400 mg	GSK2586184 400 mg OL	GSK2586184 200 mg OL
Number of subjects	14	6	2

Age categorical Units: Subjects			

Age continuous Units: years			
arithmetic mean	41.5	50.7	53.5
standard deviation	± 12.08	± 11.96	± 2.12
Gender categorical Units: Subjects			
Female	8	3	2
Male	6	3	0
Race, Customized Units: Subjects			
African American/African Heritage	0	0	0
Asian - South East Asian Heritage	0	0	0
White - White/Caucasian/European Heritage	14	6	2

Reporting group values	Total		
Number of subjects	67		
Age categorical Units: Subjects			

Age continuous Units: years			
arithmetic mean			
standard deviation	-		
Gender categorical Units: Subjects			
Female	30		
Male	37		
Race, Customized Units: Subjects			
African American/African Heritage	2		
Asian - South East Asian Heritage	1		
White - White/Caucasian/European Heritage	64		

End points

End points reporting groups

Reporting group title	Placebo
Reporting group description:	
Participants received blinded matching placebo orally as tablets, with food, twice daily (BID), for up to 12 weeks.	
Reporting group title	GSK2586184 100 mg
Reporting group description:	
Participants received blinded 100 milligrams (mg) GSK2586184 orally as tablets, with food, BID, for up to 12 weeks.	
Reporting group title	GSK2586184 200 mg
Reporting group description:	
Participants received blinded 200 mg GSK2586184 orally as tablets, with food, BID, for up to 12 weeks.	
Reporting group title	GSK2586184 400 mg
Reporting group description:	
Participants received blinded 400 mg GSK2586184 orally as tablets, with food, BID, for up to 12 weeks.	
Reporting group title	GSK2586184 400 mg OL
Reporting group description:	
Participants received Open-Label 400 mg GSK2586184 orally as tablets, with food, BID, for up to 12 weeks.	
Reporting group title	GSK2586184 200 mg OL
Reporting group description:	
Participants incorrectly received Open-Label 200 mg (rather than 400 mg) GSK2586184 orally as tablets, with food, BID, for up to 12 weeks.	
Subject analysis set title	Placebo - PP
Subject analysis set type	Per protocol
Subject analysis set description:	
Participants received blinded matching placebo orally as tablets, with food, twice daily (BID), for up to 12 weeks. The Per-Protocol (PP) Population included participants in the ITT analysis set who had no major protocol deviations.	
Subject analysis set title	GSK2586184 100 mg - PP
Subject analysis set type	Per protocol
Subject analysis set description:	
Participants received blinded 100 milligrams (mg) GSK2586184 orally as tablets, with food, BID, for up to 12 weeks. The Per-Protocol (PP) Population included participants in the ITT analysis set who had no major protocol deviations.	
Subject analysis set title	GSK2586184 200 mg - PP
Subject analysis set type	Per protocol
Subject analysis set description:	
Participants received blinded 200 mg GSK2586184 orally as tablets, with food, BID, for up to 12 weeks. The Per-Protocol (PP) Population included participants in the ITT analysis set who had no major protocol deviations.	
Subject analysis set title	GSK2586184 400 mg - PP
Subject analysis set type	Per protocol
Subject analysis set description:	
Participants received blinded 400 mg GSK2586184 orally as tablets, with food, BID, for up to 12 weeks. The Per-Protocol (PP) Population included participants in the ITT analysis set who had no major protocol deviations.	
Subject analysis set title	GSK2586184 400 mg OL - PP
Subject analysis set type	Per protocol
Subject analysis set description:	
Participants received Open-Label 400 mg GSK2586184 orally as tablets, with food, BID, for up to 12 weeks. The Per-Protocol (PP) Population included participants in the ITT analysis set who had no major protocol deviations.	

Primary: Percentage of participants who had achieved >=75% improvement from Baseline in the Psoriasis Area Severity Index (PASI) score at Week 12 (PASI 75)

End point title	Percentage of participants who had achieved >=75% improvement from Baseline in the Psoriasis Area Severity Index (PASI) score at Week 12 (PASI 75)[1]

End point description:

Psoriatic lesions were assessed using the PASI. Each area of the body (head, upper extremities, trunk and lower extremities) were assessed for the following symptoms: erythema, infiltration, desquamation. Baseline was Day 1. The percentage of participants who achieved a greater than or equal to (>=) 75% improvement from Baseline was reported with the last observation carried forward (LOCF) analysis. The Intent-to-Treat (ITT) Population included participants who received at least one dose of study medication.

End point type	Primary

End point timeframe:

Baseline and Week 12

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: There is no statistical analysis for this endpoint.

End point values	Placebo	GSK2586184 100 mg	GSK2586184 200 mg	GSK2586184 400 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	14[2]	15[3]	16[4]	14[5]
Units: Percentage of participants				
number (not applicable)	0	13	25	57

Notes:

[2] - ITT Population

[3] - ITT Population

[4] - ITT Population

[5] - ITT Population

End point values	GSK2586184 400 mg OL	GSK2586184 200 mg OL		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	6[6]	2[7]		
Units: Percentage of participants				
number (not applicable)	50	50		

Notes:

[6] - ITT Population

[7] - ITT Population

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of participants who had achieved >=75% improvement from Baseline in the Psoriasis Area Severity Index (PASI) score at Week 12 (PASI 75)

End point title	Percentage of participants who had achieved >=75% improvement from Baseline in the Psoriasis Area Severity Index (PASI) score at Week 12 (PASI 75)[8]

End point description:

Psoriatic lesions were assessed using the PASI. Each area of the body (head, upper extremities, trunk and lower extremities) were assessed for the following symptoms: erythema, infiltration, desquamation. Baseline was Day 1. The percentage of participants who achieved a greater than or equal to (>=) 75% improvement from Baseline was reported with the last observation carried forward (LOCF) analysis. The Per-Protocol (PP) Population included participants in the ITT analysis set who had no major protocol

deviations.

End point type	Primary

End point timeframe:

Baseline and Week 12

Notes:

[8] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: There is no statistical analysis for this endpoint.

End point values	Placebo - PP	GSK2586184 100 mg - PP	GSK2586184 200 mg - PP	GSK2586184 400 mg - PP
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	11[9]	14[10]	11[11]	13[12]
Units: Percentage of participants				
number (not applicable)	0	14	36	62

Notes:

[9] - PP Population

[10] - PP Population

[11] - PP Population

[12] - PP Population

End point values	GSK2586184 400 mg OL - PP			
Subject group type	Subject analysis set			
Number of subjects analysed	4[13]			
Units: Percentage of participants				
number (not applicable)	75			

Notes:

[13] - PP Population

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with any adverse event (AE) or serious adverse event (SAE)

End point title	Number of participants with any adverse event (AE) or serious adverse event (SAE)

End point description:

An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. A SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability or incapacity, or is a congenital anomaly or birth defect. Any SAEs assessed as related to study participation (e.g. study treatment, protocol-mandated procedures, invasive tests, or change in existing therapy) or related to a GSK product was recorded from the time a participant consents to participate in the study up to and including any follow-up contact.

End point type	Secondary

End point timeframe:

From the start of study up to and including the Follow-up visit (Day 112)

End point values	Placebo	GSK2586184 100 mg	GSK2586184 200 mg	GSK2586184 400 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	14[14]	15[15]	16[16]	14[17]
Units: Participants				
number (not applicable)				
Any AE	13	10	14	10
Any SAE	0	2	0	1

Notes:

[14] - ITT Population

[15] - ITT Population

[16] - ITT Population

[17] - ITT Population

End point values	GSK2586184 400 mg OL	GSK2586184 200 mg OL		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	6[18]	2[19]		
Units: Participants				
number (not applicable)				
Any AE	6	1		
Any SAE	1	0		

Notes:

[18] - ITT Population

[19] - ITT Population

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with the indicated hematology parameters falling outside of the reference range at any time post-Baseline (BL) during study

End point title	Number of participants with the indicated hematology parameters falling outside of the reference range at any time post-Baseline (BL) during study

End point description:

Hematology parameters included: basophils, eosinophils, erythrocyte mean corpuscular hemoglobin (EMCHb) EMCHb concentration (EMCHbC), erythrocyte mean corpuscular volume (EMCV), erythrocyte sedimentation rate (ESR), erythrocytes, hematocrit (fraction 1), hemoglobin, leukocytes, lymphocytes, monocytes, neutrophils, segmented neutrophils, platelets, reticulocytes. BL values were obtained at Day 1. The number of participants with the indicated hematology parameters data outside of the reference range (with high and low) any time post-BL are presented. Anytime post-BL assessments included any scheduled and unscheduled post-BL assessment. Only those participants available at the specified time points were analyzed (represented by n=X,X,X,X,X,X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the ITT Population.

End point type	Secondary

End point timeframe:

From BL (Day 1) until the Follow-up visit (Day 112)

End point values	Placebo	GSK2586184 100 mg	GSK2586184 200 mg	GSK2586184 400 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	14[20]	15[21]	16[22]	14[23]
Units: Participants				
number (not applicable)				
Basophils, low, n=13,15,16,14,6,2	0	0	0	0
Basophils, high, n=13,15,16,14,6,2	0	0	0	0
Eosinophils, low, n=13,15,16,14,6,2	3	1	0	3
Eosinophils, high, n=13,15,16,14,6,2	0	0	0	2
EMCHbC, low, n=13,15,16,14,6,2	6	5	7	5
EMCHbC, high, n=13,15,16,14,6,2	0	0	0	0
EMCHb, low, n=13,15,16,14,6,2	0	1	1	0
EMCHb, high, n=13,15,16,14,6,2	0	1	2	2
EMCV, low, n=13,15,16,14,6,2	0	0	1	0
EMCV, high, n=13,15,16,14,6,2	0	1	3	2
ESR, low, n=0,0,2,1,2,1	0	0	0	0
ESR, high, n=0,0,2,1,2,1	0	0	1	0
Erythrocytes, low, n=13,15,16,14,6,2	0	1	2	1
Erythrocytes, high, n=13,15,16,14,6,2	1	0	0	0
Hematocrit, low, n=13,15,16,14,6,2	0	0	0	2
Hematocrit, high, n=13,15,16,14,6,2	5	1	4	0
Hemoglobin, low, n=13,15,16,14,6,2	0	2	2	0
Hemoglobin, high, n=13,15,16,14,6,2	1	1	0	1
Leukocytes, low, n=13,15,16,14,6,2	0	2	3	0
Leukocytes, high, n=13,15,16,14,6,2	3	2	4	1
Lymphocytes, low, n=13,15,16,14,6,2	0	0	4	2
Lymphocytes, high, n=13,15,16,14,6,2	0	0	2	0
Monocytes, low, n=13,15,16,14,6,2	2	1	2	3
Monocytes, high, n=13,15,16,14,6,2	1	0	1	0
Neutrophils,low, n=13,15,16,14,6,2	0	1	1	1
Neutrophils, high, n=13,15,16,14,6,2	1	2	3	2
Neutrophils, Segmented, low, n=13,15,16,14,6,2	0	1	1	1
Neutrophils, Segmented, high, n=13,15,16,14,6,2	1	2	3	2
Platelets, low, n=13,15,16,14,6,2	0	1	0	1
Platelets, high, n=13,15,16,14,6,2	1	1	1	0
Reticulocytes, low, n=13,15,16,14,6,2	3	5	5	4
Reticulocytes, high, n=13,15,16,14,6,2	2	4	3	1

Notes:

[20] - ITT Population

[21] - ITT Population

[22] - ITT Population

[23] - ITT Population

End point values	GSK2586184 400 mg OL	GSK2586184 200 mg OL		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	6[24]	2[25]		
Units: Participants				
number (not applicable)				
Basophils, low, n=13,15,16,14,6,2	0	0		

Basophils, high, n=13,15,16,14,6,2	0	0		
Eosinophils, low, n=13,15,16,14,6,2	2	0		
Eosinophils, high, n=13,15,16,14,6,2	0	0		
EMCHbC, low, n=13,15,16,14,6,2	3	2		
EMCHbC, high, n=13,15,16,14,6,2	0	0		
EMCHb, low, n=13,15,16,14,6,2	0	0		
EMCHb, high, n=13,15,16,14,6,2	3	0		
EMCV, low, n=13,15,16,14,6,2	0	0		
EMCV, high, n=13,15,16,14,6,2	3	0		
ESR, low, n=0,0,2,1,2,1	0	0		
ESR, high, n=0,0,2,1,2,1	0	1		
Erythrocytes, low, n=13,15,16,14,6,2	0	0		
Erythrocytes, high, n=13,15,16,14,6,2	0	0		
Hematocrit, low, n=13,15,16,14,6,2	0	0		
Hematocrit, high, n=13,15,16,14,6,2	2	0		
Hemoglobin, low, n=13,15,16,14,6,2	0	1		
Hemoglobin, high, n=13,15,16,14,6,2	1	0		
Leukocytes, low, n=13,15,16,14,6,2	0	1		
Leukocytes, high, n=13,15,16,14,6,2	1	0		
Lymphocytes, low, n=13,15,16,14,6,2	0	0		
Lymphocytes, high, n=13,15,16,14,6,2	0	0		
Monocytes, low, n=13,15,16,14,6,2	2	0		
Monocytes, high, n=13,15,16,14,6,2	0	0		
Neutrophils,low, n=13,15,16,14,6,2	0	1		
Neutrophils, high, n=13,15,16,14,6,2	2	0		
Neutrophils, Segmented, low, n=13,15,16,14,6,2	0	1		
Neutrophils, Segmented, high, n=13,15,16,14,6,2	2	0		
Platelets, low, n=13,15,16,14,6,2	0	1		
Platelets, high, n=13,15,16,14,6,2	0	0		
Reticulocytes, low, n=13,15,16,14,6,2	0	0		
Reticulocytes, high, n=13,15,16,14,6,2	3	1		

Notes:

[24] - ITT Population

[25] - ITT Population

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with the indicated clinical chemistry parameters falling outside the reference range at any time post-Baseline (BL) during the study

End point title	Number of participants with the indicated clinical chemistry parameters falling outside the reference range at any time post-Baseline (BL) during the study

End point description:

Safety and tolerability were assessed by measuring the clinical chemistry parameters such as creatinine and cystatin C. BL values were obtained at Day 1. The number of participants with the indicated clinical chemistry parameter data outside of the reference range (> high or < low) at any time post-BL, including unscheduled or scheduled assessments, are presented. Only those participants available at the specified time points were analyzed (represented by n=X,X,X,X,X,X in the category titles).

End point type	Secondary

End point timeframe:

From Baseline (Day 1) until the Follow-up visit (Day 112)

End point values	Placebo	GSK2586184 100 mg	GSK2586184 200 mg	GSK2586184 400 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	14[26]	15[27]	16[28]	14[29]
Units: Participants				
number (not applicable)				
Creatinine, low, n=13,15,16,14,6,2	5	2	4	0
Creatinine, high, n=13,15,16,14,6,2	1	0	0	1
Cystatin C, low, n=13,15,16,14,6,2	0	0	0	2
Cystatin C, high, n=13,15,16,14,6,2	0	0	3	0

Notes:

[26] - ITT Population

[27] - ITT Population

[28] - ITT Population

[29] - ITT Population

End point values	GSK2586184 400 mg OL	GSK2586184 200 mg OL		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	6[30]	2[31]		
Units: Participants				
number (not applicable)				
Creatinine, low, n=13,15,16,14,6,2	1	0		
Creatinine, high, n=13,15,16,14,6,2	0	0		
Cystatin C, low, n=13,15,16,14,6,2	0	1		
Cystatin C, high, n=13,15,16,14,6,2	0	0		

Notes:

[30] - ITT Population

[31] - ITT Population

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with the systolic (S) and diastolic (D) blood pressure (BP) falling outside the clinical concern range at any time post-baseline during the study

End point title	Number of participants with the systolic (S) and diastolic (D) blood pressure (BP) falling outside the clinical concern range at any time post-baseline during the study

End point description:

Vital sign monitoring included systolic and diastolic BP measurements. BP measurements were taken in the supine position after 5 minutes of rest. The number of participants with the SBP or DBP outside the clinical concern range at any time post-BL are presented. SBP "low" was measured as less than 85 millimeters of mercury (mmHg)and "high" was mesaured as greater than 160 mmHg. DBP "low" was measured as less than 45 mmHg and "high" was measured as greater than 100 mmHg. The BL values were those values obtained Pre-dose on Day 1. Anytime post-BL assessments included any scheduled and unscheduled post-BL assessment. Only those participants available at the specified time points were analyzed.

End point type	Secondary

End point timeframe:

From Baseline (Day 1) until the follow-up visit (Day 112)

End point values	Placebo	GSK2586184 100 mg	GSK2586184 200 mg	GSK2586184 400 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	13[32]	15[33]	16[34]	14[35]
Units: Participants				
number (not applicable)				
SBP, low	0	0	0	0
SBP, high	1	0	0	1
DBP, low	0	0	0	0
DBP, high	3	0	0	2

Notes:

[32] - ITT Population

[33] - ITT Population

[34] - ITT Population

[35] - ITT Population

End point values	GSK2586184 400 mg OL	GSK2586184 200 mg OL		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	6[36]	2[37]		
Units: Participants				
number (not applicable)				
SBP, low	0	0		
SBP, high	1	0		
DBP, low	0	0		
DBP, high	1	0		

Notes:

[36] - ITT Population

[37] - ITT Population

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with the heart rate falling outside the clinical concern range at any time post-Baseline (BL) during the study

End point title	Number of participants with the heart rate falling outside the clinical concern range at any time post-Baseline (BL) during the study

End point description:

Vital sign monitoring included heart rate (HR) measurements. HR measurements were taken in supine position after 5 minutes of rest. The number of participants with HR outside the clinical concern range at any time post-BL are presented. HR "low" was any HR less than 40 beats per minute (bpm) and "high" was any HR greater than 110 bpm. The BL values were those values obtained Pre-dose on Day 1. Anytime post-BL assessments included any scheduled and unscheduled post-BL assessment.

End point type	Secondary

End point timeframe:

From Baseline (Day 1) until the Follow-up visit (Day 112)

End point values	Placebo	GSK2586184 100 mg	GSK2586184 200 mg	GSK2586184 400 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	13[38]	15[39]	16[40]	14[41]
Units: Participants				
number (not applicable)				
HR, low	0	0	0	0
HR, high	0	0	0	0

Notes:

[38] - ITT Population

[39] - ITT Population

[40] - ITT Population

[41] - ITT Population

End point values	GSK2586184 400 mg OL	GSK2586184 200 mg OL		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	6[42]	2[43]		
Units: Participants				
number (not applicable)				
HR, low	0	0		
HR, high	0	1		

Notes:

[42] - ITT Population

[43] - ITT Population

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in body temperature

End point title	Change from Baseline in body temperature

End point description:

Vital sign monitoring included body temperature measurements. Body temperature measurements were taken in the supine position after 5 minutes of rest.The Baseline values are those values obtained Pre-dose on Day 1. Change from Baseline was determined by subtracting the indicated time point value minus the Baseline value. Only those participants available at the specified time points were analyzed (represented by n=X,X,X,X,X in the category titles).

End point type	Secondary

End point timeframe:

From Baseline (Day 1) until the Follow-up visit (Day 112)

End point values	Placebo	GSK2586184 100 mg	GSK2586184 200 mg	GSK2586184 400 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	14[44]	15[45]	16[46]	14[47]
Units: Celsius				
arithmetic mean (standard deviation)				
Week 2, n=13,14,16,14,6,2	-0.2 (± 0.54)	0 (± 0.38)	-0.1 (± 0.73)	0 (± 0.36)
Week 4, n=12,14,14,13,6,2	-0.1 (± 0.52)	0.1 (± 0.44)	-0.1 (± 0.53)	0 (± 0.28)
Week 8, n=10,12,15,13,6,2	0.1 (± 0.44)	0.1 (± 0.51)	-0.2 (± 0.55)	-0.1 (± 0.28)
Week 12, n=10,10,14,10,6,2	-0.1 (± 0.38)	-0.2 (± 0.64)	-0.1 (± 0.38)	0 (± 0.23)
Week 16, n=8,10,12,10,6,2	0.3 (± 0.45)	-0.1 (± 0.66)	0.1 (± 0.39)	-0.1 (± 0.21)

Notes:

[44] - ITT Population

[45] - ITT Population

[46] - ITT Population

[47] - ITT Population

End point values	GSK2586184 400 mg OL	GSK2586184 200 mg OL		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	6[48]	2[49]		
Units: Celsius				
arithmetic mean (standard deviation)				
Week 2, n=13,14,16,14,6,2	0 (± 0.21)	0.6 (± 0.49)		
Week 4, n=12,14,14,13,6,2	0.3 (± 0.37)	0 (± 0)		
Week 8, n=10,12,15,13,6,2	0.2 (± 0.51)	0.1 (± 0.21)		
Week 12, n=10,10,14,10,6,2	0 (± 0.29)	0.2 (± 0)		
Week 16, n=8,10,12,10,6,2	0.4 (± 0.29)	0 (± 0.35)		

Notes:

[48] - ITT Population

[49] - ITT Population

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with the indicated maximum change from Baseline in the electrocardiogram (ECG) findings

End point title	Number of participants with the indicated maximum change from Baseline in the electrocardiogram (ECG) findings

End point description:

ECG measurements were obtained using single 12-lead ECGs with the participant in a supine position after resting in this position for at least 10 minutes. The Baseline values were those values obtained Pre-dose on Day 1. Change from Baseline was defined as the value minus the Baseline value. The QT intervals (milliseconds [msec]) corrected for heart rate using Bazett's formula (QTcB) and Fridericia's formula (QTcF) are reported.

End point type	Secondary

End point timeframe:

From Baseline (Day 1) until the Follow-up visit (Day 112)

End point values	Placebo	GSK2586184 100 mg	GSK2586184 200 mg	GSK2586184 400 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	13[50]	15[51]	16[52]	14[53]
Units: Participants				
number (not applicable)				
QTcB, <30 msec	13	14	16	12
QTcB, >=30 to <60 msec	0	1	0	2
QTcB, >60 msec	0	0	0	0
QTcF, <30 msec	13	15	16	12
QTcF, >=30 to <60 msec	0	0	0	2
QTcF, >60 msec	0	0	0	0

Notes:

[50] - ITT Population

[51] - ITT Population

[52] - ITT Population

[53] - ITT Population

End point values	GSK2586184 400 mg OL	GSK2586184 200 mg OL		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	6[54]	2[55]		
Units: Participants				
number (not applicable)				
QTcB, <30 msec	6	2		
QTcB, >=30 to <60 msec	0	0		
QTcB, >60 msec	0	0		
QTcF, <30 msec	6	2		
QTcF, >=30 to <60 msec	0	0		
QTcF, >60 msec	0	0		

Notes:

[54] - ITT Population

[55] - ITT Population

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline (BL) in the PASI score at Week 2, 4, 8 and 12

End point title	Change from Baseline (BL) in the PASI score at Week 2, 4, 8 and 12

End point description:

Psoriatic lesions were assessed using the PASI. Each area of the body (head, upper extremities, trunk and lower extremities) were assessed for the following symptoms: erythema, infiltration, desquamation. Baseline was Day 1. Only those participants available at the specified time points were analyzed (represented by n=X,X,X,X,X,X in the category titles).

End point type	Secondary

End point timeframe:

From Baseline (Day 1) until Week 12

End point values	Placebo	GSK2586184 100 mg	GSK2586184 200 mg	GSK2586184 400 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	14[56]	15[57]	16[58]	14[59]
Units: PASI score				
arithmetic mean (standard deviation)				
Week 2,n=13,14,16,14,6,2	-0.05 (± 1.716)	-2.39 (± 3.12)	-0.51 (± 7.693)	-3.94 (± 4.766)
Week 4, n=12,14,14,13,6,2	-0.73 (± 3.335)	-4.5 (± 4.344)	-7.03 (± 7.594)	-8.04 (± 7.739)
Week 8, n=10, 12,15,13,6,2	-1.41 (± 2.122)	-6.54 (± 6.915)	-8.45 (± 11.396)	-10.32 (± 8.293)
Week 12, n=10,10,14,10,6,2	-3.13 (± 2.694)	-9.76 (± 6.341)	-9.21 (± 12.446)	-13.55 (± 6.393)

Notes:

[56] - ITT Population

[57] - ITT Population

[58] - ITT Population

[59] - ITT Population

End point values	GSK2586184 400 mg OL	GSK2586184 200 mg OL		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	6[60]	2[61]		
Units: PASI score				
arithmetic mean (standard deviation)				
Week 2,n=13,14,16,14,6,2	-5.25 (± 4.192)	-3.75 (± 2.192)		
Week 4, n=12,14,14,13,6,2	-9.1 (± 3.854)	-8.2 (± 0.99)		
Week 8, n=10, 12,15,13,6,2	-7.85 (± 5.39)	-11.5 (± 0.424)		
Week 12, n=10,10,14,10,6,2	-9.37 (± 7.181)	-12.45 (± 1.061)		

Notes:

[60] - ITT Population

[61] - ITT Population

Statistical analyses

No statistical analyses for this end point

Secondary: PASI score at Week 2, 4, 8 and 12

End point title	PASI score at Week 2, 4, 8 and 12

End point description:

Psoriatic lesions were assessed using the PASI. Each area of the body (head, upper extremities, trunk and lower extremities) were assessed for the following symptoms: erythema, infiltration, desquamation. Baseline was Day 1. Only those participants available at the specified time points were analyzed (represented by n=X,X,X,X,X,X in the category titles).

End point type	Secondary

End point timeframe:

Week 2, 4, 8 and 12

End point values	Placebo	GSK2586184 100 mg	GSK2586184 200 mg	GSK2586184 400 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	14[62]	15[63]	16[64]	14[65]
Units: PASI score				
arithmetic mean (standard deviation)				
Week 2,n=13,14,16,14,6,2	16.33 (± 4.896)	16.56 (± 5.708)	18.92 (± 9.969)	13.39 (± 5.594)
Week 4, n=12,14,14,13,6,2	15.12 (± 4.683)	13.94 (± 6.616)	12.59 (± 5.524)	9.58 (± 7.91)
Week 8, n=10, 12,15,13,6,2	14.64 (± 4.289)	12.56 (± 5.442)	11.03 (± 8.322)	7.3 (± 9.11)
Week 12, n=10,10,14,10,6,2	12.92 (± 3.384)	10.52 (± 4.932)	9.67 (± 7.799)	4.03 (± 4.666)

Notes:

[62] - ITT Population

[63] - ITT Population

[64] - ITT Population

[65] - ITT Population

End point values	GSK2586184 400 mg OL	GSK2586184 200 mg OL		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	6[66]	2[67]		
Units: PASI score				
arithmetic mean (standard deviation)				
Week 2,n=13,14,16,14,6,2	13.75 (± 4.807)	11.2 (± 0.283)		
Week 4, n=12,14,14,13,6,2	9.9 (± 6.271)	6.75 (± 1.485)		
Week 8, n=10, 12,15,13,6,2	11.15 (± 9.573)	3.45 (± 2.899)		
Week 12, n=10,10,14,10,6,2	9.63 (± 10.688)	2.5 (± 3.536)		

Notes:

[66] - ITT Population

[67] - ITT Population

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of participants who had a PASI score with 50%, 75% and 90% improvement from Baseline (BL) until Week 12

End point title	Percentage of participants who had a PASI score with 50%, 75% and 90% improvement from Baseline (BL) until Week 12

End point description:

Psoriatic lesions were assessed using the PASI. Each area of the body (head, upper extremities, trunk and lower extremities) were assessed for the following symptoms: erythema, infiltration, desquamation. Baseline was Day 1. The percentage of participants who achieved greater than or equal to (>=) 50% (PASI 50) improvement from baseline, >= 75% (PASI 75) improvement from BL and >= to 90% (PASI 90) improvement from BL were reported with the last observation carried forward (LOCF) analysis.

End point type	Secondary

End point timeframe:

From Baseline (Day 1) until Week 12

End point values	Placebo	GSK2586184 100 mg	GSK2586184 200 mg	GSK2586184 400 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	14[68]	15[69]	16[70]	14[71]
Units: Percentage of Participants				
number (not applicable)				
PASI 50, Week 2	0	7	6	7
PASI 50, Week 4	0	13	25	57
PASI 50, Week 8	0	20	31	71
PASI 50, Week 12	0	27	31	64
PASI 75, Week 2	0	0	0	0
PASI 75, Week 4	0	7	6	21
PASI 75, Week 8	0	7	25	50
PASI 90, Week 2	0	0	0	0
PASI 90, Week 4	0	0	0	0
PASI 90, Week 8	0	7	6	14
PASI 90, Week 12	0	0	25	36

Notes:

[68] - ITT Population

[69] - ITT Population

[70] - ITT Population

[71] - ITT Population

End point values	GSK2586184 400 mg OL	GSK2586184 200 mg OL		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	6[72]	2[73]		
Units: Percentage of Participants				
number (not applicable)				
PASI 50, Week 2	17	0		
PASI 50, Week 4	50	100		
PASI 50, Week 8	50	100		
PASI 50, Week 12	50	100		
PASI 75, Week 2	0	0		
PASI 75, Week 4	0	0		
PASI 75, Week 8	17	50		
PASI 90, Week 2	0	0		
PASI 90, Week 4	0	0		
PASI 90, Week 8	0	0		
PASI 90, Week 12	17	50		

Notes:

[72] - ITT Population

[73] - ITT Population

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of participants who had a Physician Global Assessment

(PGA) score of 'clear' (0) or 'almost clear' (1) at Weeks 2, 4, 8 and 12

End point title	Percentage of participants who had a Physician Global Assessment (PGA) score of 'clear' (0) or 'almost clear' (1) at Weeks 2, 4, 8 and 12

End point description:

The severity of psoriatic lesions over the whole body were assessed by the investigator using the PGA scoring system. A 0 to 6 point rating scale was used, as follows: 0 = Clear (no signs of psoriasis), 1 = Almost clear (slight elevation, scale and/or erythema), 2 = Mild (mild plaque elevation, scale and/or erythema), 3 = Mild to moderate (mild plaque elevation with moderate erythema and/or scale)4 = Moderate (moderate plaque elevation, scale and/or erythema), 5 = Moderate to severe (marked plaque elevation, scale and/or erythema), 6 = Severe (very marked plaque elevation, scale and/or erythema). The Baseline value was the value obtained on Day 1. The scores were reported with the last observation carried forward (LOCF) analysis.

End point type	Secondary

End point timeframe:

Weeks 2, 4, 8 and 12

End point values	Placebo	GSK2586184 100 mg	GSK2586184 200 mg	GSK2586184 400 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	14[74]	15[75]	16[76]	14[77]
Units: Percentage of Participants				
number (not applicable)				
Week 2	0	0	6	0
Week 4	0	0	6	0
Week 8	0	7	6	29
Week 12	0	7	25	43

Notes:

[74] - ITT Population

[75] - ITT Population

[76] - ITT Population

[77] - ITT Population

End point values	GSK2586184 400 mg OL	GSK2586184 200 mg OL		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	6[78]	2[79]		
Units: Percentage of Participants				
number (not applicable)				
Week 2	0	0		
Week 4	0	0		
Week 8	0	50		
Week 12	17	50		

Notes:

[78] - ITT Population

[79] - ITT Population

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of participants in each PGA score category at Weeks 2, 4, 8

and 12

End point title	Percentage of participants in each PGA score category at Weeks 2, 4, 8 and 12

End point description:

The severity of psoriatic lesions over the whole body were assessed by the investigator using the PGA scoring system. A 0 to 6 point rating scale was used, as follows: 0 = Clear (no signs of psoriasis), 1 = Almost clear (slight elevation, scale and/or erythema), 2 = Mild (mild plaque elevation, scale and/or erythema), 3 = Mild to moderate (mild plaque elevation with moderate erythema and/or scale)4 = Moderate (moderate plaque elevation, scale and/or erythema), 5 = Moderate to severe (marked plaque elevation, scale and/or erythema), 6 = Severe (very marked plaque elevation, scale and/or erythema). The Baseline value was the value obtained on Day 1. The scores were reported with the last observation carried forward (LOCF) analysis.

End point type	Secondary

End point timeframe:

Weeks 2, 4, 8 and 12

End point values	Placebo	GSK2586184 100 mg	GSK2586184 200 mg	GSK2586184 400 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	14[80]	15[81]	16[82]	14[83]
Units: Percentage of Participants				
number (not applicable)				
Week 2, Clear, n=13,14,16,14,6,2	0	0	0	0
Week 2, almost clear, n=13,14,16,14,6,2	0	0	6	0
Week 2, mild, n=13,14,16,14,6,2	0	0	0	0
Week 2, mild to moderate, n=13,14,16,14,6,2	23	14	19	43
Week 2, moderate, n=13,14,16,14,6,2	46	64	44	36
Week 2, moderate to severe, n=13,14,16,14,6,2	31	14	13	14
Week 2, severe, n=13,14,16,14,6,2	0	7	19	7
Week 4, Clear, n=12,14,14,13,6,2	0	0	0	0
Week 4, almost clear, n=12,14,14,13,6,2	0	0	7	0
Week 4, mild, n=12,14,14,13,6,2	0	14	0	23
Week 4, mild to moderate, n=12,14,14,13,6,2	25	36	29	54
Week 4, moderate, n=12,14,14,13,6,2	50	29	43	8
Week 4, moderate to severe, n=12,14,14,13,6,2	25	14	14	15
Week 4, severe, n=12,14,14,13,6,2	0	7	7	0
Week 8, Clear, n=10,11,15,13,6,2	0	0	0	0
Week 8, almost clear, n=10,11,15,13,6,2	0	9	7	31
Week 8, mild, n=10,11,15,13,6,2	0	9	20	23
Week 8, mild to moderate, n=10,11,15,13,6,2	22	27	20	23
Week 8, moderate, n=10,11,15,13,6,2	44	36	33	8
Week 8, moderate to severe, n=10,11,15,13,6,2	33	9	13	8
Week 8, severe, n=10,11,15,13,6,2	0	9	7	8
Week 12, Clear, n=10,10,14,10,6,2	0	0	7	30

Week 12, almost clear, n=10,10,14,10,6,2	0	10	21	20
Week 12, mild, n=10,10,14,10,6,2	10	0	0	20
Week 12, mild to moderate, n=10,10,14,10,6,2	30	50	29	20
Week 12, moderate, n=10,10,14,10,6,2	50	30	21	0
Week 12, moderate to severe, n=10,10,14,10,6,2	10	10	21	0
Week 12, Severe, n=10,10,14,10,6,2	0	0	0	10

Notes:

[80] - ITT Population

[81] - ITT Population

[82] - ITT Population

[83] - ITT Population

End point values	GSK2586184 400 mg OL	GSK2586184 200 mg OL		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	6[84]	2[85]		
Units: Percentage of Participants				
number (not applicable)				
Week 2, Clear, n=13,14,16,14,6,2	0	0		
Week 2, almost clear, n=13,14,16,14,6,2	0	0		
Week 2, mild, n=13,14,16,14,6,2	0	0		
Week 2, mild to moderate, n=13,14,16,14,6,2	33	0		
Week 2, moderate, n=13,14,16,14,6,2	50	50		
Week 2, moderate to severe, n=13,14,16,14,6,2	0	50		
Week 2, severe, n=13,14,16,14,6,2	17	0		
Week 4, Clear, n=12,14,14,13,6,2	0	0		
Week 4, almost clear, n=12,14,14,13,6,2	0	0		
Week 4, mild, n=12,14,14,13,6,2	33	0		
Week 4, mild to moderate, n=12,14,14,13,6,2	33	0		
Week 4, moderate, n=12,14,14,13,6,2	17	100		
Week 4, moderate to severe, n=12,14,14,13,6,2	17	0		
Week 4, severe, n=12,14,14,13,6,2	0	0		
Week 8, Clear, n=10,11,15,13,6,2	0	0		
Week 8, almost clear, n=10,11,15,13,6,2	0	50		
Week 8, mild, n=10,11,15,13,6,2	50	0		
Week 8, mild to moderate, n=10,11,15,13,6,2	17	50		
Week 8, moderate, n=10,11,15,13,6,2	0	0		
Week 8, moderate to severe, n=10,11,15,13,6,2	33	0		
Week 8, severe, n=10,11,15,13,6,2	0	0		
Week 12, Clear, n=10,10,14,10,6,2	0	50		
Week 12, almost clear, n=10,10,14,10,6,2	17	0		
Week 12, mild, n=10,10,14,10,6,2	17	0		
Week 12, mild to moderate, n=10,10,14,10,6,2	33	50		

Week 12, moderate, n=10,10,14,10,6,2	17	0		
Week 12, moderate to severe, n=10,10,14,10,6,2	17	0		
Week 12, Severe, n=10,10,14,10,6,2	0	0		

Notes:

[84] - ITT Population

[85] - ITT Population

Statistical analyses

No statistical analyses for this end point

Secondary: Time to PASI 75

End point title	Time to PASI 75

End point description:

The time taken for participants to achieve PASI 75. Psoriatic lesions were assessed using the PASI. Each area of the body (head, upper extremities, trunk and lower extremities) were assessed for the following symptoms: erythema, infiltration, desquamation. Baseline was Day 1. The time (Days) for participants to achieve a greater than or equal to (>=) 75% improvement from Baseline was reported.

End point type	Secondary

End point timeframe:

From Baseline (Day 1) until Week 12

End point values	Placebo	GSK2586184 100 mg	GSK2586184 200 mg	GSK2586184 400 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0[86]	2[87]	4[88]	9[89]
Units: Days				
median (full range (min-max))	(to)	59 (33 to 85)	55.5 (29 to 63)	57 (27 to 85)

Notes:

[86] - ITT Population

[87] - ITT Population

[88] - ITT Population

[89] - ITT Population

End point values	GSK2586184 400 mg OL	GSK2586184 200 mg OL		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3[90]	1[91]		
Units: Days				
median (full range (min-max))	84 (56 to 85)	57 (57 to 57)		

Notes:

[90] - ITT Population

[91] - ITT Population

Statistical analyses

No statistical analyses for this end point

Secondary: Time to PGA score of 'clear' (0) or 'almost clear' (1)

End point title	Time to PGA score of 'clear' (0) or 'almost clear' (1)

End point description:

The severity of psoriatic lesions over the whole body were assessed by the investigator using the PGA scoring system. A 0 to 6 point rating scale was used, as follows: 0 = Clear (no signs of psoriasis), 1 = Almost clear (slight elevation, scale and/or erythema), 2 = Mild (mild plaque elevation, scale and/or erythema), 3 = Mild to moderate (mild plaque elevation with moderate erythema and/or scale)4 = Moderate (moderate plaque elevation, scale and/or erythema), 5 = Moderate to severe (marked plaque elevation, scale and/or erythema), 6 = Severe (very marked plaque elevation, scale and/or erythema). The Baseline value was the value obtained on Day 1. The scores were reported with the last observation carried forward (LOCF) analysis.

End point type	Secondary

End point timeframe:

From Baseline (Day 1) until Week 12

End point values	Placebo	GSK2586184 100 mg	GSK2586184 200 mg	GSK2586184 400 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0[92]	1[93]	4[94]	6[95]
Units: Days				
median (full range (min-max))	(to)	55 (55 to 55)	84.5 (15 to 85)	57 (55 to 87)

Notes:

[92] - ITT Population

[93] - ITT Population

[94] - ITT Population

[95] - ITT Population

End point values	GSK2586184 400 mg OL	GSK2586184 200 mg OL		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1[96]	1[97]		
Units: Days				
median (full range (min-max))	84 (84 to 84)	57 (57 to 57)		

Notes:

[96] - ITT Population

[97] - ITT Population

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in the itch visual analogue scale (VAS) score at Week 2, 4, 8 and 12

End point title	Change from Baseline in the itch visual analogue scale (VAS) score at Week 2, 4, 8 and 12

End point description:

Participants rated the intensity of itch over the past week by marking a line on the VAS, a 10 centimeter (cm) long scale. A line placed on the left indicated no noticeable itching sensation and a line placed on the right indicated maximum itching sensation). The Baseline value was the value obtained on Day 1. The change from Baseline was the difference between post-Baseline and Baseline. Only those participants available at the specified time points were analyzed (represented by n=X,X,X,X,X,X in the category titles).

End point type	Secondary

End point timeframe:

From Baseline (Day 1) until Week 12

End point values	Placebo	GSK2586184 100 mg	GSK2586184 200 mg	GSK2586184 400 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	14[98]	15[99]	16[100]	14[101]
Units: Change from baseline				
arithmetic mean (standard deviation)				
Week 2,n=12,14,15,12,6,2	-5.67 (± 32.129)	-14.79 (± 31.396)	-14.87 (± 23.67)	-24.92 (± 24.737)
Week 4,n=10,12,14,12,6,2	-7 (± 37.944)	-26.5 (± 28.659)	-22.36 (± 27.244)	-28.08 (± 25.678)
Week 8,n=9,11,14,10,6,2	0.22 (± 26.138)	-26.27 (± 35.707)	-24.86 (± 37.134)	-36.3 (± 29.788)
Week 12,n=9,10,13,8,5,2	-1.56 (± 34.348)	-21.4 (± 40.533)	-23.92 (± 40.586)	-41.13 (± 31.791)

Notes:

[98] - ITT Population

[99] - ITT Population

[100] - ITT Population

[101] - ITT Population

End point values	GSK2586184 400 mg OL	GSK2586184 200 mg OL		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	6[102]	2[103]		
Units: Change from baseline				
arithmetic mean (standard deviation)				
Week 2,n=12,14,15,12,6,2	-56.33 (± 30.329)	-22 (± 43.841)		
Week 4,n=10,12,14,12,6,2	-47.5 (± 39.48)	-30 (± 62.225)		
Week 8,n=9,11,14,10,6,2	-61.5 (± 31.729)	-32.5 (± 65.761)		
Week 12,n=9,10,13,8,5,2	-60.8 (± 38.16)	-25 (± 76.368)		

Notes:

[102] - ITT Population

[103] - ITT Population

Statistical analyses

No statistical analyses for this end point

Secondary: Itch VAS scores at Week 2, 4, 8 and 12

End point title	Itch VAS scores at Week 2, 4, 8 and 12

End point description:

Participants rated the intensity of itch over the past week by marking a line on the VAS, a 10 cm long scale. A line placed on the left indicated no noticeable itching sensation and a line placed on the right indicated maximum itching sensation). Only those participants available at the specified time points were analyzed (represented by n=X,X,X,X,X,X in the category titles).

End point type	Secondary

End point timeframe:

Week 2, 4, 8 and 12

End point values	Placebo	GSK2586184 100 mg	GSK2586184 200 mg	GSK2586184 400 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	14[104]	15[105]	16[106]	14[107]
Units: VAS scores				
arithmetic mean (standard deviation)				
Week 2,n=12,14,15,12,6,2	46.42 (± 28.909)	41.64 (± 21.995)	42.07 (± 31.176)	22.92 (± 21.707)
Week 4,n=10,12,14,13,6,2	44.4 (± 35.485)	33.42 (± 25.939)	32.57 (± 30.729)	23.85 (± 23.14)
Week 8,n=9,11,14,11,6,2	57.33 (± 29.368)	31.55 (± 29.156)	29.93 (± 29.437)	14.45 (± 21.92)
Week 12,n=9,10,13,9,5,2	50.67 (± 37.683)	39.5 (± 33.58)	30.08 (± 34.697)	14 (± 23.701)

Notes:

[104] - ITT Population

[105] - ITT Population

[106] - ITT Population

[107] - ITT Population

End point values	GSK2586184 400 mg OL	GSK2586184 200 mg OL		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	6[108]	2[109]		
Units: VAS scores				
arithmetic mean (standard deviation)				
Week 2,n=12,14,15,12,6,2	11.83 (± 14.73)	42 (± 22.627)		
Week 4,n=10,12,14,13,6,2	20.67 (± 30.051)	34 (± 41.012)		
Week 8,n=9,11,14,11,6,2	6.67 (± 7.763)	31.5 (± 44.548)		
Week 12,n=9,10,13,9,5,2	5.4 (± 6.693)	39 (± 55.154)		

Notes:

[108] - ITT Population

[109] - ITT Population

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline of Dermatology Life Quality Index (DLQI) score at Week 12

End point title	Change from Baseline of Dermatology Life Quality Index (DLQI) score at Week 12

End point description:

The DLQI was used to assess quality of life. Participants completed the questionnaire to evaluate how their psoriasis affected their life over the week before the assessment took place. Each of the 10 questions was scored out of 0–3 as; 0 = Not at all, 1 = A little, 2 = A lot and 3 = Very much. The Baseline value was the value obtained on Day 1. The change from Baseline was the difference between post- Baseline and Baseline. Only those participants who had a Week 12 evaluation were analyzed.

End point type	Secondary

End point timeframe:

Baseline and Week 12

End point values	Placebo	GSK2586184 100 mg	GSK2586184 200 mg	GSK2586184 400 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	10[110]	10[111]	14[112]	10[113]
Units: Change from baseline				
arithmetic mean (standard deviation)	1.7 (± 5.638)	-2.8 (± 7.743)	-4.29 (± 8.389)	-8 (± 3.83)

Notes:

[110] - ITT Population

[111] - ITT Population

[112] - ITT Population

[113] - ITT Population

End point values	GSK2586184 400 mg OL	GSK2586184 200 mg OL		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	4[114]	2[115]		
Units: Change from baseline				
arithmetic mean (standard deviation)	-6.75 (± 5.123)	-8 (± 11.314)		

Notes:

[114] - ITT Population

[115] - ITT Population

Statistical analyses

No statistical analyses for this end point

Secondary: Population pharmacokinetic (PK) derived area under the concentration-time curve from time zero (pre-dose) to the time of the last measureable concentration AUC(0-tau) of GSK2586184

End point title	Population pharmacokinetic (PK) derived area under the concentration-time curve from time zero (pre-dose) to the time of the last measureable concentration AUC(0-tau) of GSK2586184

End point description:

Blood samples were taken to measure plasma concentrations of GSK2586184. A two-compartment model with a three-compartment transit model was used to derive PK parameters. The PK Population comprised of all participants who were randomized and received at least one dose of study medication.

End point type	Secondary

End point timeframe:

From Baseline (Day 1) until Week 12

End point values	Placebo	GSK2586184 100 mg	GSK2586184 200 mg	GSK2586184 400 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0[116]	15[117]	15[118]	14[119]
Units: Nanogram/milliLitre*hour (ng/mL*hr)				
geometric mean (geometric coefficient of variation)	()	1464.079 (± 43.9)	3516.962 (± 38.7)	7768.408 (± 62.4)

Notes:

[116] - PK Population

[117] - PK Population

[118] - PK Population

[119] - PK Population

End point values	GSK2586184 400 mg OL	GSK2586184 200 mg OL		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	6[120]	2[121]		
Units: Nanogram/milliLitre*hour (ng/mL*hr)				
geometric mean (geometric coefficient of variation)	7561.88 (± 79.1)	3208.205 (± 53.5)		

Notes:

[120] - PK Population

[121] - PK Population

Statistical analyses

No statistical analyses for this end point

Secondary: Clearance of GSK2586184

End point title	Clearance of GSK2586184

End point description:

Blood samples were taken to measure plasma concentrations of GSK2586184. A two-compartment model with a three-compartment transit model was used to derive PK parameters. The PK Population comprised of all participants who were randomized and received at least one dose of study medication.

End point type	Secondary

End point timeframe:

From Baseline (Day 1) until Week 12

End point values	Placebo	GSK2586184 100 mg	GSK2586184 200 mg	GSK2586184 400 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0[122]	15[123]	15[124]	14[125]
Units: Litre (L)/hr				
geometric mean (geometric coefficient of variation)	()	68.30232 (± 43.9)	56.86726 (± 38.7)	51.4906 (± 62.4)

Notes:

[122] - PK Population

[123] - PK Population

[124] - PK Population

[125] - PK Population

End point values	GSK2586184 400 mg OL	GSK2586184 200 mg OL		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	6[126]	2[127]		
Units: Litre (L)/hr				
geometric mean (geometric coefficient of variation)	52.8969 (± 79.1)	62.34017 (± 53.5)		

Notes:

[126] - PK Population

[127] - PK Population

Statistical analyses

No statistical analyses for this end point

Secondary: Steady state volume of distribution (Vss) of GSK2586184

End point title	Steady state volume of distribution (Vss) of GSK2586184

End point description:

Blood samples were taken to measure plasma concentrations of GSK2586184. A two-compartment model with a three-compartment transit model was used to derive PK parameters. The PK Population comprised of all participants who were randomized and received at least one dose of study medication.

End point type	Secondary

End point timeframe:

From Baseline (Day 1) until Week 12

End point values	Placebo	GSK2586184 100 mg	GSK2586184 200 mg	GSK2586184 400 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0[128]	15[129]	15[130]	14[131]
Units: Liters (L)				
geometric mean (geometric coefficient of variation)	()	244.1026 (± 62.3)	193.7534 (± 47.1)	186.7832 (± 64.4)

Notes:

[128] - PK Population

[129] - PK Population

[130] - PK Population

[131] - PK Population

End point values	GSK2586184 400 mg OL	GSK2586184 200 mg OL		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	6[132]	2[133]		
Units: Liters (L)				
geometric mean (geometric coefficient of variation)	199.7375 (± 85.4)	216.0036 (± 66.5)		

Notes:

[132] - PK Population

[133] - PK Population

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline in serum neopterin concentrations at Weeks 2, 4, 8 and 12

End point title	Change from baseline in serum neopterin concentrations at Weeks 2, 4, 8 and 12

End point description:

Serum Neopterin is a marker of psoriatic disease activity. Blood samples were collected for estimation of serum neoprotein concentration. Baseline was Day 1.

End point type	Secondary

End point timeframe:

From Baseline (Day 1) until Week 12

End point values	Placebo	GSK2586184 100 mg	GSK2586184 200 mg	GSK2586184 400 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	14[134]	15[135]	16[136]	14[137]
Units: Change from baseline (nmol/L)				
arithmetic mean (standard deviation)				
Week 2,n=13,14,14,12,6,2	0.19 (± 1.219)	0.43 (± 5.394)	2.35 (± 6.475)	-0.42 (± 1.858)
Week 4, n=10,14,13,10,6,2	0.18 (± 0.844)	-1.69 (± 2.933)	-1.15 (± 1.768)	-0.69 (± 1.195)
Week 8, n=10,12,15,11,5,2	-0.14 (± 0.597)	-1.13 (± 2.312)	-0.81 (± 2.294)	0.31 (± 2.998)
Week 12, n= 8,9,14,9,6,2	-0.01 (± 1.038)	-1.32 (± 2.355)	-0.79 (± 1.738)	4.37 (± 13.387)

Notes:

[134] - ITT Population

[135] - ITT Population

[136] - ITT Population

[137] - ITT Population

End point values	GSK2586184 400 mg OL	GSK2586184 200 mg OL		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	6[138]	2[139]		
Units: Change from baseline (nmol/L)				
arithmetic mean (standard deviation)				
Week 2,n=13,14,14,12,6,2	-0.47 (± 0.918)	9.95 (± 13.93)		
Week 4, n=10,14,13,10,6,2	-0.67 (± 0.378)	1.8 (± 2.828)		
Week 8, n=10,12,15,11,5,2	-0.4 (± 1.52)	0.15 (± 2.192)		

Week 12, n= 8,9,14,9,6,2	-0.42 (± 1.182)	0.35 (± 0.212)		

Notes:

[138] - ITT Population

[139] - ITT Population

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Non-serious Adverse Events (AEs) were collected from the start of study treatment up to and including the Follow-up visit (up to Study Week 16), Serious AEs were recorded from the time of consent to treatment up to and including the Follow-up visit.

Adverse event reporting additional description:

SAEs and non-serious AEs are reported for the Intent-to-Treat Population, comprised of all participants who received at least one dose of study medication.

Assessment type	Systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	16

Reporting groups

Reporting group title	Placebo

Reporting group description:

Participants received blinded matching placebo orally as tablets, with food, twice daily (BID), for up to 12 weeks.

Reporting group title	GSK2586184 100 mg

Reporting group description:

Participants received blinded 100 milligrams (mg) GSK2586184 orally as tablets, with food, BID, for up to 12 weeks.

Reporting group title	GSK2586184 200 mg

Reporting group description:

Participants received blinded 200 mg GSK2586184 orally as tablets, with food, BID, for up to 12 weeks.

Reporting group title	GSK2586184 400 mg

Reporting group description:

Participants received blinded 400 mg GSK2586184 orally as tablets, with food, BID, for up to 12 weeks.

Reporting group title	GSK2586184 400 mg OL

Reporting group description:

Participants received Open-Label 400 mg GSK2586184 orally as tablets, with food, BID, for up to 12 weeks.

Reporting group title	GSK2586184 200 mg OL

Reporting group description:

Participants incorrectly received Open-Label 200 mg (rather than 400 mg) GSK2586184 orally as tablets, with food, BID, for up to 12 weeks.

Serious adverse events	Placebo	GSK2586184 100 mg	GSK2586184 200 mg
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 14 (0.00%)	2 / 15 (13.33%)	0 / 16 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events			
Injury, poisoning and procedural complications			
Ligament rupture			

subjects affected / exposed	0 / 14 (0.00%)	1 / 15 (6.67%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Concussion			
subjects affected / exposed	0 / 14 (0.00%)	1 / 15 (6.67%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Thrombocytopenia			
subjects affected / exposed	0 / 14 (0.00%)	1 / 15 (6.67%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 14 (0.00%)	0 / 15 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Calculus ureteric			
subjects affected / exposed	0 / 14 (0.00%)	0 / 15 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	GSK2586184 400 mg	GSK2586184 400 mg OL	GSK2586184 200 mg OL
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 14 (7.14%)	1 / 6 (16.67%)	0 / 2 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events			
Injury, poisoning and procedural complications			
Ligament rupture			
subjects affected / exposed	0 / 14 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Concussion			

subjects affected / exposed	0 / 14 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Thrombocytopenia			
subjects affected / exposed	0 / 14 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	1 / 14 (7.14%)	0 / 6 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Calculus ureteric			
subjects affected / exposed	0 / 14 (0.00%)	1 / 6 (16.67%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Placebo	GSK2586184 100 mg	GSK2586184 200 mg
Total subjects affected by non-serious adverse events			
subjects affected / exposed	13 / 14 (92.86%)	10 / 15 (66.67%)	14 / 16 (87.50%)
Vascular disorders			
Hypertension			
subjects affected / exposed	0 / 14 (0.00%)	0 / 15 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Hot flush			
subjects affected / exposed	0 / 14 (0.00%)	1 / 15 (6.67%)	0 / 16 (0.00%)
occurrences (all)	0	7	0
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	1 / 14 (7.14%)	3 / 15 (20.00%)	0 / 16 (0.00%)
occurrences (all)	1	4	0

Pyrexia			
subjects affected / exposed	0 / 14 (0.00%)	2 / 15 (13.33%)	0 / 16 (0.00%)
occurrences (all)	0	2	0
Chills			
subjects affected / exposed	0 / 14 (0.00%)	1 / 15 (6.67%)	0 / 16 (0.00%)
occurrences (all)	0	1	0
Feeling hot			
subjects affected / exposed	1 / 14 (7.14%)	0 / 15 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Malaise			
subjects affected / exposed	0 / 14 (0.00%)	0 / 15 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Immune system disorders			
Hypersensitivity			
subjects affected / exposed	0 / 14 (0.00%)	0 / 15 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	0 / 14 (0.00%)	1 / 15 (6.67%)	1 / 16 (6.25%)
occurrences (all)	0	1	2
Psychiatric disorders			
Nightmare			
subjects affected / exposed	0 / 14 (0.00%)	0 / 15 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Investigations			
Blood cholesterol increased			
subjects affected / exposed	0 / 14 (0.00%)	0 / 15 (0.00%)	2 / 16 (12.50%)
occurrences (all)	0	0	2
Blood triglycerides increased			
subjects affected / exposed	1 / 14 (7.14%)	0 / 15 (0.00%)	1 / 16 (6.25%)
occurrences (all)	1	0	1
Alanine aminotransferase increased			
subjects affected / exposed	0 / 14 (0.00%)	0 / 15 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Low density lipoprotein increased			

subjects affected / exposed	0 / 14 (0.00%)	0 / 15 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Injury, poisoning and procedural complications			
Limb injury			
subjects affected / exposed	0 / 14 (0.00%)	0 / 15 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Lip injury			
subjects affected / exposed	0 / 14 (0.00%)	0 / 15 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Post procedural complication			
subjects affected / exposed	1 / 14 (7.14%)	0 / 15 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Road traffic accident			
subjects affected / exposed	1 / 14 (7.14%)	0 / 15 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Skin injury			
subjects affected / exposed	0 / 14 (0.00%)	1 / 15 (6.67%)	0 / 16 (0.00%)
occurrences (all)	0	1	0
Cardiac disorders			
Tachycardia			
subjects affected / exposed	0 / 14 (0.00%)	1 / 15 (6.67%)	1 / 16 (6.25%)
occurrences (all)	0	1	1
Nervous system disorders			
Headache			
subjects affected / exposed	5 / 14 (35.71%)	5 / 15 (33.33%)	3 / 16 (18.75%)
occurrences (all)	9	5	5
Dizziness			
subjects affected / exposed	0 / 14 (0.00%)	3 / 15 (20.00%)	0 / 16 (0.00%)
occurrences (all)	0	3	0
Burning sensation			
subjects affected / exposed	0 / 14 (0.00%)	0 / 15 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Migraine			
subjects affected / exposed	0 / 14 (0.00%)	0 / 15 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Somnolence			

subjects affected / exposed	0 / 14 (0.00%)	0 / 15 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	1 / 14 (7.14%)	0 / 15 (0.00%)	0 / 16 (0.00%)
occurrences (all)	2	0	0
Eye disorders			
Visual impairment			
subjects affected / exposed	0 / 14 (0.00%)	0 / 15 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
Nausea			
subjects affected / exposed	2 / 14 (14.29%)	1 / 15 (6.67%)	0 / 16 (0.00%)
occurrences (all)	2	1	0
Abdominal pain upper			
subjects affected / exposed	1 / 14 (7.14%)	1 / 15 (6.67%)	2 / 16 (12.50%)
occurrences (all)	1	1	2
Diarrhoea			
subjects affected / exposed	2 / 14 (14.29%)	2 / 15 (13.33%)	0 / 16 (0.00%)
occurrences (all)	3	2	0
Abdominal pain			
subjects affected / exposed	0 / 14 (0.00%)	2 / 15 (13.33%)	0 / 16 (0.00%)
occurrences (all)	0	2	0
Abdominal distension			
subjects affected / exposed	0 / 14 (0.00%)	0 / 15 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Constipation			
subjects affected / exposed	0 / 14 (0.00%)	0 / 15 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Dyspepsia			
subjects affected / exposed	1 / 14 (7.14%)	0 / 15 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Eructation			
subjects affected / exposed	1 / 14 (7.14%)	0 / 15 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Food poisoning			

subjects affected / exposed	0 / 14 (0.00%)	0 / 15 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 14 (0.00%)	0 / 15 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Inguinal hernia			
subjects affected / exposed	0 / 14 (0.00%)	0 / 15 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Tongue coated			
subjects affected / exposed	0 / 14 (0.00%)	0 / 15 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Toothache			
subjects affected / exposed	0 / 14 (0.00%)	0 / 15 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Vomiting			
subjects affected / exposed	0 / 14 (0.00%)	0 / 15 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Skin and subcutaneous tissue disorders			
Pruritus			
subjects affected / exposed	2 / 14 (14.29%)	2 / 15 (13.33%)	0 / 16 (0.00%)
occurrences (all)	3	2	0
Psoriasis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 15 (0.00%)	3 / 16 (18.75%)
occurrences (all)	0	0	3
Pruritus generalised			
subjects affected / exposed	0 / 14 (0.00%)	0 / 15 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Acne			
subjects affected / exposed	0 / 14 (0.00%)	0 / 15 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Cold sweat			
subjects affected / exposed	1 / 14 (7.14%)	0 / 15 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Dermatitis contact			
subjects affected / exposed	0 / 14 (0.00%)	1 / 15 (6.67%)	0 / 16 (0.00%)
occurrences (all)	0	1	0

Eczema			
subjects affected / exposed	0 / 14 (0.00%)	0 / 15 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Guttate psoriasis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 15 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Rash papular			
subjects affected / exposed	0 / 14 (0.00%)	1 / 15 (6.67%)	0 / 16 (0.00%)
occurrences (all)	0	1	0
Skin fissures			
subjects affected / exposed	0 / 14 (0.00%)	0 / 15 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	1 / 14 (7.14%)	1 / 15 (6.67%)	0 / 16 (0.00%)
occurrences (all)	1	1	0
Back pain			
subjects affected / exposed	0 / 14 (0.00%)	0 / 15 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Arthritis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 15 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Growing pains			
subjects affected / exposed	0 / 14 (0.00%)	0 / 15 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Muscle spasms			
subjects affected / exposed	0 / 14 (0.00%)	0 / 15 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	3
Muscle tightness			
subjects affected / exposed	0 / 14 (0.00%)	1 / 15 (6.67%)	0 / 16 (0.00%)
occurrences (all)	0	1	0
Musculoskeletal pain			
subjects affected / exposed	0 / 14 (0.00%)	0 / 15 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Pain in extremity			

subjects affected / exposed	0 / 14 (0.00%)	0 / 15 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Psoriatic arthropathy			
subjects affected / exposed	0 / 14 (0.00%)	0 / 15 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
Nasopharyngitis			
subjects affected / exposed	3 / 14 (21.43%)	5 / 15 (33.33%)	4 / 16 (25.00%)
occurrences (all)	3	7	4
Cystitis			
subjects affected / exposed	1 / 14 (7.14%)	0 / 15 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Influenza			
subjects affected / exposed	0 / 14 (0.00%)	1 / 15 (6.67%)	0 / 16 (0.00%)
occurrences (all)	0	1	0
Abscess limb			
subjects affected / exposed	0 / 14 (0.00%)	0 / 15 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Acne pustular			
subjects affected / exposed	0 / 14 (0.00%)	0 / 15 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Bacterial disease carrier			
subjects affected / exposed	0 / 14 (0.00%)	0 / 15 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Enterobiasis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 15 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal viral infection			
subjects affected / exposed	0 / 14 (0.00%)	0 / 15 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Gingivitis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 15 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Post procedural infection			
subjects affected / exposed	1 / 14 (7.14%)	0 / 15 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0

Sinusitis			
subjects affected / exposed	0 / 14 (0.00%)	1 / 15 (6.67%)	0 / 16 (0.00%)
occurrences (all)	0	1	0
Tinea pedis			
subjects affected / exposed	1 / 14 (7.14%)	0 / 15 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Tooth abscess			
subjects affected / exposed	0 / 14 (0.00%)	0 / 15 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Urinary tract infection			
subjects affected / exposed	1 / 14 (7.14%)	0 / 15 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Metabolism and nutrition disorders			
Hypertriglyceridaemia			
subjects affected / exposed	0 / 14 (0.00%)	1 / 15 (6.67%)	0 / 16 (0.00%)
occurrences (all)	0	1	0
Vitamin B12 deficiency			
subjects affected / exposed	0 / 14 (0.00%)	0 / 15 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0

Non-serious adverse events	GSK2586184 400 mg	GSK2586184 400 mg OL	GSK2586184 200 mg OL
Total subjects affected by non-serious adverse events			
subjects affected / exposed	10 / 14 (71.43%)	6 / 6 (100.00%)	1 / 2 (50.00%)
Vascular disorders			
Hypertension			
subjects affected / exposed	0 / 14 (0.00%)	2 / 6 (33.33%)	0 / 2 (0.00%)
occurrences (all)	0	2	0
Hot flush			
subjects affected / exposed	0 / 14 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	1 / 14 (7.14%)	0 / 6 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0
Pyrexia			

subjects affected / exposed	0 / 14 (0.00%)	0 / 6 (0.00%)	1 / 2 (50.00%)
occurrences (all)	0	0	2
Chills			
subjects affected / exposed	0 / 14 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Feeling hot			
subjects affected / exposed	0 / 14 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Malaise			
subjects affected / exposed	1 / 14 (7.14%)	0 / 6 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0
Immune system disorders			
Hypersensitivity			
subjects affected / exposed	0 / 14 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	0 / 14 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			
Nightmare			
subjects affected / exposed	0 / 14 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Investigations			
Blood cholesterol increased			
subjects affected / exposed	0 / 14 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Blood triglycerides increased			
subjects affected / exposed	0 / 14 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Alanine aminotransferase increased			
subjects affected / exposed	0 / 14 (0.00%)	1 / 6 (16.67%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Low density lipoprotein increased			
subjects affected / exposed	0 / 14 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0

Injury, poisoning and procedural complications			
Limb injury			
subjects affected / exposed	1 / 14 (7.14%)	0 / 6 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0
Lip injury			
subjects affected / exposed	0 / 14 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Post procedural complication			
subjects affected / exposed	0 / 14 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Road traffic accident			
subjects affected / exposed	0 / 14 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Skin injury			
subjects affected / exposed	0 / 14 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Cardiac disorders			
Tachycardia			
subjects affected / exposed	0 / 14 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Nervous system disorders			
Headache			
subjects affected / exposed	3 / 14 (21.43%)	2 / 6 (33.33%)	1 / 2 (50.00%)
occurrences (all)	4	6	1
Dizziness			
subjects affected / exposed	1 / 14 (7.14%)	0 / 6 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0
Burning sensation			
subjects affected / exposed	0 / 14 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Migraine			
subjects affected / exposed	1 / 14 (7.14%)	0 / 6 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0
Somnolence			
subjects affected / exposed	1 / 14 (7.14%)	0 / 6 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0

Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	0 / 14 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Eye disorders			
Visual impairment			
subjects affected / exposed	1 / 14 (7.14%)	0 / 6 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0
Gastrointestinal disorders			
Nausea			
subjects affected / exposed	2 / 14 (14.29%)	1 / 6 (16.67%)	0 / 2 (0.00%)
occurrences (all)	3	3	0
Abdominal pain upper			
subjects affected / exposed	0 / 14 (0.00%)	1 / 6 (16.67%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Diarrhoea			
subjects affected / exposed	1 / 14 (7.14%)	0 / 6 (0.00%)	0 / 2 (0.00%)
occurrences (all)	2	0	0
Abdominal pain			
subjects affected / exposed	0 / 14 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Abdominal distension			
subjects affected / exposed	1 / 14 (7.14%)	0 / 6 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0
Constipation			
subjects affected / exposed	1 / 14 (7.14%)	0 / 6 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0
Dyspepsia			
subjects affected / exposed	0 / 14 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Eructation			
subjects affected / exposed	0 / 14 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Food poisoning			
subjects affected / exposed	1 / 14 (7.14%)	0 / 6 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0
Gastrooesophageal reflux disease			

subjects affected / exposed	1 / 14 (7.14%)	0 / 6 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0
Inguinal hernia			
subjects affected / exposed	0 / 14 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Tongue coated			
subjects affected / exposed	0 / 14 (0.00%)	1 / 6 (16.67%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Toothache			
subjects affected / exposed	0 / 14 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Vomiting			
subjects affected / exposed	1 / 14 (7.14%)	0 / 6 (0.00%)	0 / 2 (0.00%)
occurrences (all)	2	0	0
Skin and subcutaneous tissue disorders			
Pruritus			
subjects affected / exposed	0 / 14 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Psoriasis			
subjects affected / exposed	0 / 14 (0.00%)	1 / 6 (16.67%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Pruritus generalised			
subjects affected / exposed	0 / 14 (0.00%)	1 / 6 (16.67%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Acne			
subjects affected / exposed	1 / 14 (7.14%)	0 / 6 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0
Cold sweat			
subjects affected / exposed	0 / 14 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Dermatitis contact			
subjects affected / exposed	0 / 14 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Eczema			
subjects affected / exposed	1 / 14 (7.14%)	0 / 6 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0

Guttate psoriasis			
subjects affected / exposed	0 / 14 (0.00%)	1 / 6 (16.67%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Rash papular			
subjects affected / exposed	0 / 14 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Skin fissures			
subjects affected / exposed	0 / 14 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 14 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Back pain			
subjects affected / exposed	1 / 14 (7.14%)	0 / 6 (0.00%)	1 / 2 (50.00%)
occurrences (all)	1	0	2
Arthritis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 6 (0.00%)	1 / 2 (50.00%)
occurrences (all)	0	0	3
Growing pains			
subjects affected / exposed	0 / 14 (0.00%)	0 / 6 (0.00%)	1 / 2 (50.00%)
occurrences (all)	0	0	1
Muscle spasms			
subjects affected / exposed	0 / 14 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Muscle tightness			
subjects affected / exposed	0 / 14 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal pain			
subjects affected / exposed	0 / 14 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Pain in extremity			
subjects affected / exposed	0 / 14 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Psoriatic arthropathy			

subjects affected / exposed	0 / 14 (0.00%)	0 / 6 (0.00%)	1 / 2 (50.00%)
occurrences (all)	0	0	2
Infections and infestations			
Nasopharyngitis			
subjects affected / exposed	5 / 14 (35.71%)	1 / 6 (16.67%)	0 / 2 (0.00%)
occurrences (all)	7	1	0
Cystitis			
subjects affected / exposed	1 / 14 (7.14%)	0 / 6 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0
Influenza			
subjects affected / exposed	1 / 14 (7.14%)	0 / 6 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0
Abscess limb			
subjects affected / exposed	0 / 14 (0.00%)	1 / 6 (16.67%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Acne pustular			
subjects affected / exposed	1 / 14 (7.14%)	0 / 6 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0
Bacterial disease carrier			
subjects affected / exposed	0 / 14 (0.00%)	1 / 6 (16.67%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Enterobiasis			
subjects affected / exposed	1 / 14 (7.14%)	0 / 6 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0
Gastrointestinal viral infection			
subjects affected / exposed	0 / 14 (0.00%)	1 / 6 (16.67%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Gingivitis			
subjects affected / exposed	1 / 14 (7.14%)	0 / 6 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0
Post procedural infection			
subjects affected / exposed	0 / 14 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Sinusitis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0

Tinea pedis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Tooth abscess			
subjects affected / exposed	0 / 14 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Urinary tract infection			
subjects affected / exposed	0 / 14 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Metabolism and nutrition disorders			
Hypertriglyceridaemia			
subjects affected / exposed	0 / 14 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Vitamin B12 deficiency			
subjects affected / exposed	0 / 14 (0.00%)	1 / 6 (16.67%)	0 / 2 (0.00%)
occurrences (all)	0	1	0

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
06 March 2013	(Germany only) To further clarify the dermatological withdrawal criteria, in response to a request by the Ethics Committee in Germany.
09 July 2013	To update the relevant sections of the protocol following the release of new monkey toxicology data.
30 October 2013	To revise the contraception requirements for male subjects with female partners of reproductive potential, and revise reporting and follow up requirements for pregnancies in female partners of male subjects, following a safety evaluation review.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported